CFTR modulator theratyping: Current status, gaps and future directions
John P. Clancy(Cystic Fibrosis Foundation), Katherine L. Tuggle(University of Alabama at Birmingham), Scott H. Donaldson(University of North Carolina at Chapel Hill), William R. Skach(Cystic Fibrosis Foundation), Donald R. VanDevanter(Case Western Reserve University), Martina Gentzsch(University of North Carolina at Chapel Hill), Jeffrey M. Beekman(University Medical Center Utrecht), Anthony G. Durmowicz(Cystic Fibrosis Foundation), Jerry A. Nick(National Jewish Health), Drucy Borowitz(University at Buffalo, State University of New York), Robert J. Bridges(Rosalind Franklin University of Medicine and Science), Philip Thomas(University of Applied Sciences Worms), Elizabeth Joseloff(Cystic Fibrosis Foundation), Eric J. Sorscher(Emory University), Steven M. Rowe(University of Alabama at Birmingham), J. Wallenburg(Cystic Fibrosis Canada), Calvin U. Cotton(Case Western Reserve University), George M. Solomon(University of Alabama), K. De Boeck(University Medical Center Utrecht), Garry R. Cutting(Johns Hopkins University), Christopher M. Penland(Cystic Fibrosis Foundation), Anjaparavanda P. Naren(Cedars-Sinai Medical Center), Hermann Bihler(Cystic Fibrosis Foundation), Margarida D. Amaral(University of Lisbon), Beate Illek(UCSF Benioff Children's Hospital), Michael Boyle(McMaster University), Martin Mense(Cystic Fibrosis Foundation), John E. Mahoney(Cystic Fibrosis Foundation)
Cited by 288
Related Papers
Update on Key Emerging Challenges in Cystic Fibrosis
|Medical Principles and Practice|2014|3.7k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k